PubMed Health⌕ Search

PubMed · 2646032

Proficiency testing in a medical-needs context.

Abstract

Proficiency testing by State and Federal agencies is an ongoing activity of clinical laboratories and an occasional source of anxiety; strict statistical evaluations of "snapshot" laboratory values are inappropriate and medical-needs criteria should be used. The quality of laboratory results largely depends on available technology. Fortunately, for most of the common clinical chemistry analytes there has been a steady reduction of imprecision during the past 20 years. Proficiency testing may have been the stimulus for this improved performance. Medical-needs criteria differ, depending on the testing goal. For proficiency testing, population screening criteria are appropriate, e.g., the College of American Pathologists fixed criteria for the common tests. Stricter criteria are needed for short-term (inpatient) and long-term (outpatient) monitoring of laboratory data. Explicit proficiency-testing limits are given here for nine of the common clinical chemistry tests for each of the three medical-needs criteria described above. The limits consider total error--i.e., bias from the believed correct value, and imprecision. Rather broad limits are acceptable for the commonly performed enzyme tests when used for screening purposes.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J A Lott, N R Manning, M K Kyler. 1989. Proficiency testing in a medical-needs context.. https://pubmed.ncbi.nlm.nih.gov/2646032/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Detection of Delta9-tetrahydrocannabinolic acid A in human urine and blood serum by LC-MS/MS.

Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) is the precursor of Delta9-tetrahydrocannabinol (Delta9-THC) in hemp plants. During smoking, the non-psychoactive Delta9-THCA-A is converted to Delta9-THC, the main psychoactive component of marihuana and hashish. Although the decarboxylation of Delta9-THCA-A to Delta9-THC was assumed to be complete--which means that no Delta9-THCA-A should be detectable in urine and blood serum of cannabis consumers--we found Delta9-THCA-A in the urine and blood serum samples collected from police controls of drivers suspected for driving under the influence of drugs (DUID). For LC-MS/MS analysis, urine and blood serum samples were prepared by solid-phase extraction. Analysis was performed with a phenylhexyl column using gradient elution with acetonitrile. For detection of Delta9-THCA-A, the mass spectrometer (MS) (SCIEX API 365 triple-quadrupole MS with TurboIonSpray source) was operated in the multiple reaction monitoring (MRM) mode using the following transitions: m/z357 --> 313, m/z357 --> 245 and m/z357 --> 191. Delta9-THCA-A could be detected in the urine and blood serum samples of several cannabis consumers in concentrations of up to 10.8 ng/ml in urine and 14.8 ng/ml in serum. The concentration of Delta9-THCA-A was below the Delta9-THC concentration in most serum samples, resulting in molar ratios of Delta9-THCA-A/Delta9-THC of approximately 5.0-18.6%. Only in one case, where a short elapsed time between the last intake and blood sampling is assumed, the molar ratio was 18.6% in the serum. This indicates differences in elimination kinetics, which need to be investigated in detail.

Blood Chemical Analysis↗